INTERNATIONAL MEETING OF WORLD PHARMACOPOEIAS
29 February to 2 March 2012
WHO, Geneva, Executive Board Room

Answers from pharmacopoeias
1. Name of pharmacopoeia

FARMACOPEIA PORTUGUESA
PORTUGUESE PHARMACOPOEIA
(including the translation of the European Pharmacopoeia)
Besides being obviously referred in the legislation from Portugal, it is also accepted in the legislation from Brasil and other countries where Portuguese is an official language (Moçambique, Guiné or S.Tomé e Princípe, for instance)
National/regional legislation includes reference to other

- National Pharmacopoeias
  
  *United States Pharmacopoeia, Pharmacopoeia of Japan, British Pharmacopoeia or any other pharmacopoeia from an European country*

- Regional Pharmacopoeias
  
  *European Pharmacopoeia*

- International Pharmacopoeias - No
4. Publication of latest edition

- The Farmacopeia Portuguesa 9 was published from 2008 until 2010

- The publication of Farmacopeia Portuguesa 10 will start during 2012
5. Update frequency

As the European Pharmacopoeia, Farmacopeia Portuguesa is published every four years, with three supplements each year.
6. For which products does the pharmacopoeia provide specifications?

- APIs
- Dosage forms – Human and Veterinary use
- Herbal products
- Biologicals

The role of the **Formulário Galénico Português** (Portuguese Galenic Formulary) – from 2001
7. Number of texts included in the pharmacopoeia

- monographs for APIs – Ph.Eur.
- monographs for finished dosage forms: about 85
- monographs for biologicals – Ph.Eur.
- general monographs – Ph.Eur.
- supplementary texts – Ph.Eur. and a text concerning the use of coloring agents in dosage forms
8. Collaboration with and/or being part of a (different) national/regional pharmacopoeia

- European Pharmacopoeia
9. Publication of harmonized pharmacopoeial texts within the pharmacopoeia

- Only the harmonized texts included in the European Pharmacopoeia
10. Interaction with stakeholders, including regulators

- Interaction with the Portuguese regulators
11. Strategy for the future

– To continue the collaboration with the European Pharmacopoeia

– To update the national texts

– To tighten the links with the Portuguese speaking countries

– To tighten the links with stakeholders (regulators, manufacturers of APIs and manufacturers of medicines).